SCOPUS 정보 검색 플랫폼

Journal of Clinical Oncology

Volumn 30, Issue 5, 2012, Pages 469-470

Targeted therapy for chronic lymphocytic leukemia: A glimpse into the future

(1) Hillmen, Peter a

a St James's Institute of Oncology (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LENALIDOMIDE; NAVITOCLAX; OBATOCLAX; OBLIMERSEN; OFATUMUMAB; PCI 32765; PLERIXAFOR; PROTEIN BCL 2; RITUXIMAB; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; NEUTROPENIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MUTATION; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; THALIDOMIDE; THIONUCLEOTIDES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84856945306 PISSN: 0732183X EISSN: 15277755 Source Type: Journal
DOI: 10.1200/JCO.2011.37.8612 Document Type: Editorial

Times cited : (2)

References (15)

1
- 84863116430
- Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of phase I study of navitoclax in patients with relapsed or refractory disease
- Roberts AW, Seymour JF, Brown JR, et al: Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30:488-496, 2012
- (2012) J Clin Oncol , vol.30 , pp. 488-496
- Roberts, A.W.¹ Seymour, J.F.² Brown, J.R.³

2
- 77952952903
- The role of Bcl-2 family proteins in chronic lymphocytic leukaemia
- Buggins AG, Pepper CJ: The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res 34:837-842, 2010
- (2010) Leuk Res , vol.34 , pp. 837-842
- Buggins, A.G.¹ Pepper, C.J.²

3
- 20044372326
- In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells
- DOI 10.1172/JCI200523409
- Messmer BT, Messmer D, Allen SL, et al: In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 115:755-764, 2005 (Pubitemid 40322252)
- (2005) Journal of Clinical Investigation , vol.115 , Issue.3 , pp. 755-764
- Messmer, B.T.¹ Messmer, D.² Allen, S.L.³ Kolitz, J.E.⁴ Kudalkar, P.⁵ Cesar, D.⁶ Murphy, E.J.⁷ Koduru, P.⁸ Ferrarini, M.⁹ Zupo, S.¹⁰ Cutrona, G.¹¹ Damle, R.N.¹² Wasil, T.¹³ Rai, K.R.¹⁴ Hellerstein, M.K.¹⁵ Chiorazzi, N.¹⁶

4
- 32944475363
- Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia
- DOI 10.1200/JCO.2005.02.4364
- O'Brien SM, Cunningham CC, Golenkov AK, et al: Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia. J Clin Oncol 23:7697-7702, 2005 (Pubitemid 46291834)
- (2005) Journal of Clinical Oncology , vol.23 , Issue.30 , pp. 7697-7702
- O'Brien, S.M.¹ Cunningham, C.C.² Golenkov, A.K.³ Turkina, A.G.⁴ Novick, S.C.⁵ Rai, K.R.⁶

5
- 58849164097
- Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia
- O'Brien SM, Claxton DF, Crump M, et al: Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113:299-305, 2009
- (2009) Blood , vol.113 , pp. 299-305
- O'Brien, S.M.¹ Claxton, D.F.² Crump, M.³

6
- 0030048565
- Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro
- Panayiotidis P, Jones D, Ganeshaguru K, et al: Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 92:97-103, 1996 (Pubitemid 26018774)
- (1996) British Journal of Haematology , vol.92 , Issue.1 , pp. 97-103
- Panayiotidis, P.¹ Jones, D.² Ganeshaguru, K.³ Foroni, L.⁴ Hoffbrand, A.V.⁵

7
- 0026696155
- Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells
- Schena M, Larsson LG, Gottardi D, et al: Growth- and differentiation- associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 79:2981-2989, 1992
- (1992) Blood , vol.79 , pp. 2981-2989
- Schena, M.¹ Larsson, L.G.² Gottardi, D.³

8
- 78649792807
- The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia
- Packham G, Stevenson F: The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia. Semin Cancer Biol 20:391-399, 2010
- (2010) Semin Cancer Biol , vol.20 , pp. 391-399
- Packham, G.¹ Stevenson, F.²

9
- 77957201023
- Phosphatidylinositol 3-kinase-δinhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
- Herman SE, Gordon AL, Wagner AJ, et al: Phosphatidylinositol 3-kinase-δinhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116:2078-2088, 2010
- (2010) Blood , vol.116 , pp. 2078-2088
- Herman, S.E.¹ Gordon, A.L.² Wagner, A.J.³

10
- 84872213122
- CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 delta, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia
- Presented at abstr 55
- Furman RR, Byrd JC, Brown JR, et al: CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 delta, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Presented at ASH Annual Meeting, Orlando, FL, December 4-7, 2010 (abstr 55)
- ASH Annual Meeting, Orlando, FL, December 4-7, 2010
- Furman, R.R.¹ Byrd, J.C.² Brown, J.R.³

11
- 79959404661
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- Herman SE, Gordon AL, Hertlein E, et al: Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117:6287-6296, 2011
- (2011) Blood , vol.117 , pp. 6287-6296
- Herman, S.E.¹ Gordon, A.L.² Hertlein, E.³

12
- 84856858792
- The Bruton's tyrosine kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): An update on ongoing phase 1 studies
- Presented at abstr 57
- Burger JA, O'Brien S, Fowler N, et al: The Bruton's tyrosine kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): An update on ongoing phase 1 studies. Presented at ASH Annual Meeting, Orlando, FL, December 4-7, 2010 (abstr 57)
- ASH Annual Meeting, Orlando, FL, December 4-7, 2010
- Burger, J.A.¹ O'Brien, S.² Fowler, N.³

13
- 33947243663
- Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study
- DOI 10.1200/JCO.2005.05.0401
- Chanan-Khan A, Miller KC, Musial L, et al: Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study. J Clin Oncol 24:5343-5349, 2006 (Pubitemid 46623164)
- (2006) Journal of Clinical Oncology , vol.24 , Issue.34 , pp. 5343-5349
- Chanan-Khan, A.¹ Miller, K.C.² Musial, L.³ Lawrence, D.⁴ Padmanabhan, S.⁵ Takeshita, K.⁶ Porter, C.W.⁷ Goodrich, D.W.⁸ Bernstein, Z.P.⁹ Wallace, P.¹⁰ Spaner, D.¹¹ Mohr, A.¹² Byrne, C.¹³ Hernandez-Ilizaliturri, F.¹⁴ Chrystal, C.¹⁵ Starostik, P.¹⁶ Czuczman, M.S.¹⁷

14
- 84855463714
- Preliminary results from a phase I dose escalation study to determine the maximum tolerated dose of plerixafor in combination with rituximab in patients with relapsed chronic lymphocytic leukemia
- abstr 0772
- Andritsos LA, Byrd JC, Hewes B, et al: Preliminary results from a phase I dose escalation study to determine the maximum tolerated dose of plerixafor in combination with rituximab in patients with relapsed chronic lymphocytic leukemia. Haematologica 95:321, 2010 (suppl 2; abstr 0772)
- (2010) Haematologica , vol.95 , Issue.SUPPL. 2 , pp. 321
- Andritsos, L.A.¹ Byrd, J.C.² Hewes, B.³

15
- 79551504914
- TP53 mutation and survival in chronic lymphocytic leukemia
- Zenz T, Eichhorst B, Busch R, et al: TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 28:4473-4479, 2010
- (2010) J Clin Oncol , vol.28 , pp. 4473-4479
- Zenz, T.¹ Eichhorst, B.² Busch, R.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.